Q-omics provides the consensus-scored SRSF9P1 profile across patient tissues and cancer cell-line models. SRSF9P1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, SRSF9P1 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, SRSF9P1 RNA expression shows 15,956 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight PAAD, KIRC, and TGCT as cancer lineages where SRSF9P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SRSF9P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SRSF9P1 survival associations across molecular data types. SRSF9P1 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SRSF9P1 RNA expression–survival associations across cancer types. High SRSF9P1 expression shows unfavorable associations in LGG, SARC and KIRP, but favorable associations in PAAD, HNSC and UCEC. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for SRSF9P1 RNA expression.
This table summarizes SRSF9P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SRSF9P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SRSF9P1 shows lower tumor expression in HNSC and higher tumor expression in KIRC, BLCA, BRCA, LUAD and LIHC. The KIRC box plot shows higher SRSF9P1 RNA expression in tumor versus normal tissue (log2 FC = +0.741, t-test p < 0.001).
This table shows molecular features associated with SRSF9P1 in patient tissues and cancer cell lines. In patient samples, SRSF9P1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
